PT102152A - Pelete de fluoxetina enterica - Google Patents

Pelete de fluoxetina enterica Download PDF

Info

Publication number
PT102152A
PT102152A PT102152A PT10215298A PT102152A PT 102152 A PT102152 A PT 102152A PT 102152 A PT102152 A PT 102152A PT 10215298 A PT10215298 A PT 10215298A PT 102152 A PT102152 A PT 102152A
Authority
PT
Portugal
Prior art keywords
pelete
fluoxetin
enterprise
fluoxetin enterprise
enterprise pelete
Prior art date
Application number
PT102152A
Other languages
English (en)
Other versions
PT102152B (pt
Inventor
Peter Lloyd Oren
Neil Robert Anderson
Roger Garrick Harrison
Daniel Frederick Lynch
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25349313&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT102152(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PT102152A publication Critical patent/PT102152A/pt
Publication of PT102152B publication Critical patent/PT102152B/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
PT102152A 1997-05-29 1998-05-08 Pelete de fluoxetina enterica PT102152B (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/867,196 US5910319A (en) 1997-05-29 1997-05-29 Fluoxetine enteric pellets and methods for their preparation and use

Publications (2)

Publication Number Publication Date
PT102152A true PT102152A (pt) 1998-12-31
PT102152B PT102152B (pt) 2000-09-29

Family

ID=25349313

Family Applications (1)

Application Number Title Priority Date Filing Date
PT102152A PT102152B (pt) 1997-05-29 1998-05-08 Pelete de fluoxetina enterica

Country Status (46)

Country Link
US (3) US5910319A (pt)
JP (1) JP3210288B2 (pt)
KR (1) KR100549473B1 (pt)
CN (2) CN1161109C (pt)
AR (1) AR011728A1 (pt)
AT (1) AT408068B (pt)
AU (1) AU726690B2 (pt)
BE (1) BE1011925A3 (pt)
BR (1) BR9801989A (pt)
CA (1) CA2234826C (pt)
CH (1) CH693018A5 (pt)
CO (1) CO4940407A1 (pt)
CZ (1) CZ290582B6 (pt)
DE (1) DE19823940B4 (pt)
DK (1) DK176776B1 (pt)
ES (1) ES2161574B1 (pt)
FI (1) FI119971B (pt)
FR (1) FR2763846B1 (pt)
GB (1) GB2325623B (pt)
GR (1) GR980100188A (pt)
HK (1) HK1034902A1 (pt)
HU (1) HUP9800882A3 (pt)
ID (1) ID20343A (pt)
IL (1) IL124073A (pt)
IT (1) ITMI980908A1 (pt)
LT (1) LT4477B (pt)
LU (1) LU90245B1 (pt)
LV (1) LV12176B (pt)
MY (1) MY118139A (pt)
NL (1) NL1009259C2 (pt)
NO (1) NO317743B1 (pt)
NZ (1) NZ330192A (pt)
PE (1) PE75399A1 (pt)
PL (1) PL192293B1 (pt)
PT (1) PT102152B (pt)
RO (1) RO120043B1 (pt)
RS (1) RS49827B (pt)
RU (1) RU2164405C2 (pt)
SE (1) SE522914C2 (pt)
SG (1) SG72805A1 (pt)
SI (1) SI9800128B (pt)
SV (1) SV1998000052A (pt)
TR (1) TR199800937A2 (pt)
TW (1) TWI239838B (pt)
UA (1) UA48193C2 (pt)
ZA (1) ZA983173B (pt)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2752732B1 (fr) * 1996-08-28 1998-11-20 Pf Medicament Forme galenique a liberation prolongee de milnacipran
IE990406A1 (en) 1999-05-20 2000-12-27 Elan Corp Plc Multiparticulate controlled release selective serotonin reuptake inhibitor formulations.
JP2003500348A (ja) * 1999-05-20 2003-01-07 エラン コーポレーシヨン ピーエルシー 多粒子状制御放出選択的セロトニン再吸収阻害剤製剤
ES2162560B1 (es) * 1999-06-25 2002-07-16 Rodriguez Concepcion Pena Uso de fluoxetina, paroxetina y otros isrs para la fabricacion de medicamentos con el fin de aumentar la capacidad de abstenerse de substancias o actividades que crean dependencia.
PL211402B1 (pl) * 1999-09-03 2012-05-31 Apbi Holdings Zastosowanie dapoksetyny do leczenia lub zwalczania przedwczesnej ejakulacji
CN1094347C (zh) * 1999-11-15 2002-11-20 广东药学院药物研究所 一种治疗前列腺良性增生症的控释微丸及其制备方法
US6273260B1 (en) 2000-03-08 2001-08-14 Eli Lilly And Company Pharmaceutical packaging system
ES2185452B2 (es) * 2000-08-01 2004-03-16 Cinfa S A Lab Composicion farmaceutica de fluoxetina en comprimido dispersable recubierto y su proceso de fabricacion.
JP4181738B2 (ja) * 2000-08-25 2008-11-19 信越化学工業株式会社 腸溶性コーティング製剤の製造方法
US6482440B2 (en) * 2000-09-21 2002-11-19 Phase 2 Discovery, Inc. Long acting antidepressant microparticles
AU2002212102A1 (en) * 2000-11-08 2002-05-21 Aeromatic-Fielder Ag A process for production of particles for pharmaceutical compositions having increased bioavailability
US20040170688A1 (en) * 2001-08-06 2004-09-02 Deshmukh Abhijit Mukund Enteric formulation of fluoxetin
CA2457385A1 (en) 2001-08-06 2003-02-20 Dr. Reddy's Laboratories Ltd. Improved enteric formulation of fluoxetin
US20040220153A1 (en) * 2002-09-24 2004-11-04 Jost-Price Edward Roydon Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
AU2002361495A1 (en) * 2002-12-24 2004-07-22 Lupin Limited Enteric coated fluoxetine composition
US8614247B2 (en) * 2003-04-10 2013-12-24 Institut National De La Sante Et De La Recherche Medicale Methods for preventing, attenuating or treating pulmonary hypertension using a serotonin transporter inhibitor, and pharmaceutical compositions for the treatment thereof
SG141430A1 (en) 2003-05-30 2008-04-28 Ranbaxy Lab Ltd Substituted pyrrole derivatives and their use as hmg-co inhibitors
US20050176693A1 (en) * 2003-08-12 2005-08-11 Boissonneault Roger M. Method of intermittent administration of a pharmaceutical for the treatment of conditions associated with a female's menstrual cycle
US20070141150A1 (en) * 2003-12-30 2007-06-21 Raghupathi Kandarapu Pharmaceutical composition
WO2005105045A1 (ja) * 2004-04-30 2005-11-10 Astellas Pharma Inc. 経口投与用時限放出型粒子状医薬組成物及び該組成物を含有する口腔内速崩壊錠
KR100920856B1 (ko) * 2004-11-30 2009-10-09 (주)아모레퍼시픽 선택적 세로토닌 재흡수 억제제의 연장방출 제제 및 그제조방법
JP2007523213A (ja) * 2004-12-23 2007-08-16 テバ ファーマシューティカル インダストリーズ リミティド 医薬的に許容できるデュロキセチンの塩及びその中間体の調製方法
WO2007015270A2 (en) * 2005-08-02 2007-02-08 Lupin Limited Novel controlled release compositions of selective serotonin reuptake inhibitors
US20070155820A1 (en) * 2005-11-23 2007-07-05 Auspex Pharmaceuticals, Inc. Substituted aryloxypropylamines with serotoninergic and/or norepinephrinergic activity
BRPI0618379A2 (pt) 2005-11-08 2011-08-30 Ranbaxy Lab Ltd processo para preparação do hemi-sal de cálcio do ácido (3r,5r) -7-[2-(4-fluorofenil)-5-isopropil-3-fenil-4-[(4-hidroxime tilfenilamino) carbonil]-pirrol-1-il] -3, 5-diidroxi heptanóico
EP1863782A1 (en) * 2005-12-05 2007-12-12 Teva Pharmaceutical Industries Ltd. 2-(n-methyl-propanamine)-3-(2-naphtol) thiophene, an imputity of duloxetine hydrochloride
KR20080094837A (ko) * 2006-02-24 2008-10-24 테바 파마슈티컬 인더스트리즈 리미티드 플루바스타틴 나트륨 약학 조성물
CN101057837B (zh) * 2006-04-20 2010-12-22 湖南九典制药有限公司 一种右旋酮洛芬肠溶微丸及制备方法
EP2016066A4 (en) * 2006-05-10 2010-11-24 Reddys Lab Ltd Dr PROCESS FOR PREPARING DULOXETINE
US20070292511A1 (en) * 2006-05-22 2007-12-20 Gershon Kolatkar Duloxetine hydrochloride delayed release formulations
US20100297226A1 (en) * 2006-06-01 2010-11-25 Dexcel Pharma Technologies Ltd. Multiple unit pharmaceutical formulation
JP5052051B2 (ja) * 2006-06-16 2012-10-17 トーアエイヨー株式会社 腸溶性顆粒剤及びその製造方法
WO2008014175A2 (en) * 2006-07-28 2008-01-31 Dr. Reddy's Laboratories Ltd. Granular pharmaceutical compositions
US20080033050A1 (en) 2006-08-04 2008-02-07 Richards Patricia Allison Tewe Method of treating thermoregulatory disfunction with paroxetine
WO2008020286A2 (en) * 2006-08-14 2008-02-21 Torrent Pharmaceuticals Limited Pharmaceutical compositions of duloxetine
WO2008036846A2 (en) * 2006-09-22 2008-03-27 Braincells, Inc. Combination comprising an hmg-coa reductase inhibitor and a second neurogenic agent for treating a nervous system disorder and increasing neurogenesis
US20080226711A1 (en) * 2007-03-12 2008-09-18 Torrent Pharmaceuticals Ltd. Pharmaceutical compositions of duloxetine
US20090226517A1 (en) * 2008-02-06 2009-09-10 Vinita Umashankar Vyas Pharmaceutical formulations comprising duloxetine
AP2975A (en) 2008-07-16 2014-09-30 Richter Gedeon Nyrt Pharmaceutical formulations containing dopamine receptor ligands
US20110172249A1 (en) * 2008-09-03 2011-07-14 Takeda Pharmaceutical Company Limted Method for improving absorbability of preparation, and preparation having improved absorbability
CN101804145B (zh) * 2009-02-12 2012-11-14 杭州赛利药物研究所有限公司 一种大蒜油肠溶微丸胶囊及其制备方法
EP2477614A2 (en) * 2009-09-17 2012-07-25 Cadila Healthcare Limited Pharmaceutical compositions for reducing alcohol-induced dose dumping
TW201141544A (en) 2010-02-22 2011-12-01 Daiichi Sankyo Co Ltd Oral solid extended release dosage form
JP6397813B2 (ja) * 2012-05-02 2018-09-26 キャプシュゲル・ベルジウム・エヌ・ヴィ ヒドロキシプロピルメチルセルロースアセテートスクシネート（ｈｐｍｃａｓ）の水性分散液
CN102716084B (zh) * 2012-06-29 2013-09-25 海南美大制药有限公司 盐酸氟西汀脂质体固体制剂
CA2883077C (en) 2012-09-03 2017-03-07 Daiichi Sankyo Company, Limited Hydromorphone hydrochloride-containing oral sustained-release pharmaceutical composition
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
JP6190080B2 (ja) * 2014-05-20 2017-08-30 ダウ グローバル テクノロジーズ エルエルシー エステル化セルロースエーテルを含むカプセル殻
US10179110B2 (en) 2014-05-20 2019-01-15 Dow Global Technologies Llc Dispersion comprising a partially neutralized esterified cellulose ether
WO2015187874A1 (en) * 2014-06-07 2015-12-10 Structure-Ase, Inc. A method for the detection and/or diagnosis of eating disorders and malnutrition using x-ray diffraction
US10471152B2 (en) 2014-08-29 2019-11-12 Capsugel Belgium Nv Colloidal dispersion comprising HPMCAS
US20170042806A1 (en) 2015-04-29 2017-02-16 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
US11274087B2 (en) 2016-07-08 2022-03-15 Richter Gedeon Nyrt. Industrial process for the preparation of cariprazine
MA52457A (fr) * 2017-04-13 2021-03-10 Chase Therapeutics Corp Combinaison pharmaceutique et son utilisation pour le traitement de synucléinopathies
HUP1700253A1 (hu) 2017-06-13 2019-01-28 Richter Gedeon Nyrt Szilárd orális gyógyszerkészítmények
CN107898942B (zh) * 2017-11-24 2021-01-26 一力制药(罗定)有限公司 一种感冒清热胶囊及其制备方法
US11547707B2 (en) 2019-04-10 2023-01-10 Richter Gedeon Nyrt. Carbamoyl cyclohexane derivatives for treating autism spectrum disorder
WO2022115054A1 (en) * 2020-11-27 2022-06-02 Santa Farma Ilac Sanayii A.S. Enteric coated duloxetine compositions

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4018895A (en) 1974-01-10 1977-04-19 Eli Lilly And Company Aryloxyphenylpropylamines in treating depression
US4626549A (en) * 1974-01-10 1986-12-02 Eli Lilly And Company Treatment of obesity with aryloxyphenylpropylamines
US4194009A (en) 1974-01-10 1980-03-18 Eli Lilly And Company Aryloxyphenylpropylamines for obtaining a psychotropic effect
US4314081A (en) * 1974-01-10 1982-02-02 Eli Lilly And Company Arloxyphenylpropylamines
JPS517116A (en) 1974-06-11 1976-01-21 Shinetsu Chemical Co Choyoseihifukuyakuzaino seizohoho
CH649216A5 (de) 1979-08-16 1985-05-15 Sandoz Ag Verfahren zur auftragung eines magensaftresistenten filmes auf einen heilmittelkern und feste einheitsdosierungsform mit magensaftresistentem film.
JPS5855125B2 (ja) * 1980-03-10 1983-12-08 信越化学工業株式会社 固形薬剤用腸溶性コ−テイング剤組成物
US4444778A (en) * 1981-08-27 1984-04-24 Coughlin Shaun R Method and composition for treating atherosclerosis
US4797286A (en) 1985-11-12 1989-01-10 Eli Lilly And Company Orally administerable sustained release pharmaceutical formulations
US4847092A (en) * 1985-11-12 1989-07-11 Eli Lilly And Company Orally administerable sustained release pharmaceutical formulations
GB2189699A (en) 1986-04-30 1987-11-04 Haessle Ab Coated acid-labile medicaments
US4918242A (en) 1988-03-30 1990-04-17 Aldrich Chemical Company, Inc. Novel optically 1,3-phenoxypropylhalides
CA1337955C (en) * 1988-09-26 1996-01-23 Thomas A. Almquist Recoating of stereolithographic layers
US4999382A (en) * 1988-10-26 1991-03-12 Massachusetts Institute Of Technology Compositions for treating tobacco withdrawal symptoms and methods for their use
US5356934A (en) * 1990-03-29 1994-10-18 Eli Lilly And Company Selected serotonin subtype receptor agonist to treat sleep apnea
US5589511A (en) * 1990-08-13 1996-12-31 Sepracor Inc. Method for treating migraine headaches using optically pure S(+) fluoxetine
US5104899A (en) * 1990-08-13 1992-04-14 Sepracor, Inc. Methods and compositions for treating depression using optically pure fluoxetine
JPH04202124A (ja) * 1990-11-29 1992-07-22 Fuji Kagaku Kogyo Kk 噴霧乾燥造粒法による薬物放出の制御された製剤の製造法
WO1992013452A1 (en) * 1991-02-04 1992-08-20 Young James W Methods of use and compositions of r(-) fluoxetine
EP0720478A1 (en) * 1991-05-07 1996-07-10 Dynagen, Inc. A controlled, sustained release delivery system for smoking cessation
EP0632720B1 (en) * 1992-03-25 1998-11-11 Depomed Systems, Inc. Hydroxyethylcellulose-based sustained-release oral drug dosage froms
US5518730A (en) * 1992-06-03 1996-05-21 Fuisz Technologies Ltd. Biodegradable controlled release flash flow melt-spun delivery system
JPH06293633A (ja) * 1993-04-05 1994-10-21 Shin Etsu Chem Co Ltd 水性腸溶性エマルジョンの製造方法
US5362886A (en) 1993-10-12 1994-11-08 Eli Lilly And Company Asymmetric synthesis
WO1995012385A1 (en) * 1993-11-03 1995-05-11 Isotech Medical, Inc. Microparticular pharmaceutical compositions in micellar form
CA2134038C (en) * 1994-06-16 1997-06-03 David Taiwai Wong Potentiation of drug response
US5508276A (en) * 1994-07-18 1996-04-16 Eli Lilly And Company Duloxetine enteric pellets
ES2082723B1 (es) * 1994-07-20 1996-10-01 Lilly Sa Formulacion farmaceutica de fluoxetina en forma dispersable.
JPH08109126A (ja) * 1994-10-07 1996-04-30 Amano Pharmaceut Co Ltd 耐衝撃性腸溶性顆粒剤およびこれを含有する錠剤
JPH08245423A (ja) * 1995-03-06 1996-09-24 Shionogi & Co Ltd 水系腸溶性コーティング液
GB9514842D0 (en) * 1995-07-20 1995-09-20 Smithkline Beecham Plc Novel formulation

Also Published As

Publication number Publication date
MY118139A (en) 2004-09-30
CH693018A5 (de) 2003-01-31
PL326134A1 (en) 1998-12-07
GR980100188A (el) 1999-01-29
LU90245A1 (pt) 1998-11-30
ZA983173B (en) 1999-10-15
KR19980086622A (ko) 1998-12-05
US5910319A (en) 1999-06-08
FR2763846A1 (fr) 1998-12-04
CN1161109C (zh) 2004-08-11
ES2161574B1 (es) 2002-06-16
PT102152B (pt) 2000-09-29
JPH10330253A (ja) 1998-12-15
NO982197L (no) 1998-11-30
AT408068B (de) 2001-08-27
SI9800128A (sl) 1999-02-28
DE19823940A1 (de) 1998-12-03
TR199800937A3 (tr) 1999-10-21
ITMI980908A1 (it) 1999-10-28
NZ330192A (en) 1999-08-30
KR100549473B1 (ko) 2006-03-23
ID20343A (id) 1998-12-03
IL124073A (en) 2002-02-10
CA2234826A1 (en) 1998-11-29
LT98058A (en) 1998-10-26
CN1285189A (zh) 2001-02-28
RS49827B (sr) 2008-08-07
NO982197D0 (no) 1998-05-14
HK1034902A1 (en) 2001-11-09
PL192293B1 (pl) 2006-09-29
RU2164405C2 (ru) 2001-03-27
ES2161574A1 (es) 2001-12-01
RO120043B1 (ro) 2005-08-30
ATA93198A (de) 2001-01-15
LV12176A (lv) 1998-12-20
US5985322A (en) 1999-11-16
SI9800128B (sl) 2000-04-30
JP3210288B2 (ja) 2001-09-17
GB2325623A (en) 1998-12-02
AU6904898A (en) 1998-12-03
FI980846A0 (fi) 1998-04-16
AR011728A1 (es) 2000-08-30
DE19823940B4 (de) 2010-04-29
USRE39030E1 (en) 2006-03-21
NL1009259C2 (nl) 1998-12-01
FI980846A (fi) 1998-11-30
IE980284A1 (en) 2000-07-12
GB9807939D0 (en) 1998-06-10
CN1200924A (zh) 1998-12-09
DK176776B1 (da) 2009-08-10
TWI239838B (en) 2005-09-21
PE75399A1 (es) 1999-08-17
HUP9800882A2 (hu) 2000-03-28
BR9801989A (pt) 2000-02-08
TR199800937A2 (xx) 1999-10-21
AU726690B2 (en) 2000-11-16
LV12176B (en) 1999-03-20
HU9800882D0 (en) 1998-05-28
CZ114398A3 (cs) 1998-12-16
HUP9800882A3 (en) 2000-07-28
SG72805A1 (en) 2000-05-23
GB2325623B (en) 1999-04-14
SE522914C2 (sv) 2004-03-16
SV1998000052A (es) 1999-03-16
NO317743B1 (no) 2004-12-13
BE1011925A3 (fr) 2000-03-07
CO4940407A1 (es) 2000-07-24
CA2234826C (en) 2000-12-19
YU16598A (en) 1999-11-22
UA48193C2 (uk) 2002-08-15
CZ290582B6 (cs) 2002-08-14
LT4477B (lt) 1999-03-25
SE9801336L (sv) 1998-11-30
FR2763846B1 (fr) 2001-05-18
LU90245B1 (fr) 2002-07-31
CN1212834C (zh) 2005-08-03
SE9801336D0 (sv) 1998-04-17
FI119971B (fi) 2009-05-29

Similar Documents

Publication Publication Date Title
PT102152A (pt) Pelete de fluoxetina enterica
ID18090A (id) Mikrokapsul menggunakan iminooksadiazinadiona poliisosianat
PT973746E (pt) 3-ciano-quinolinas substituidas
DE69835466D1 (de) Optischer Verstärker
ID17053A (id) Derivat-derivat 2-(2-okso-etiliden)-imidazolidin-4-on
DE69713026T2 (de) Positioniervorrichtung
FI972739A0 (fi) Foerfarande och system foer kommunikation
ID18010A (id) Oligosakarida termodifikasi
IDP000009398A (id) Serat geser-dispersi
PT1036083E (pt) Novos 9a-azalidos
DE59813487D1 (de) Substituierte 4-benzoyl-pyrazole
DK1036014T3 (da) Afstandsholder
DK0983266T3 (da) Hidtil ukendte tetrahydrosioquinolinthiophencarboximidamider
DE29703911U1 (de) Spannschloß
DK0960100T3 (da) Substituerede 4-benzoyl-pyrazoler
BR9708893A (pt) Ferniluracilas substituidas
BR9711681A (pt) Novos m-todos
PT1015447E (pt) Derivado piperidinilmetiloxazolidinona
ID24079A (id) Aminoheteroksiklilamida tersubstitusi
DE59807877D1 (de) Substituierte 4-benzoyl-pyrazole
DE29717565U1 (de) Segment
KR970007831U (ko) 김밥 말이용 김발
FR2752100B1 (fr) Laser
DE29709628U1 (de) Abstandhaltevorrichtung
DE59810960D1 (de) Substituierte phenyluracile

Legal Events

Date Code Title Description
BB1A Laying open of patent application

Effective date: 19980727

FG3A Patent granted, date of granting

Effective date: 20000614